+

WO1996027595A1 - Heterocyclylcarboxamides et autres composes utilises pour le traitement des arythmies cardiaques - Google Patents

Heterocyclylcarboxamides et autres composes utilises pour le traitement des arythmies cardiaques Download PDF

Info

Publication number
WO1996027595A1
WO1996027595A1 PCT/EP1995/000872 EP9500872W WO9627595A1 WO 1996027595 A1 WO1996027595 A1 WO 1996027595A1 EP 9500872 W EP9500872 W EP 9500872W WO 9627595 A1 WO9627595 A1 WO 9627595A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
pharmaceutically acceptable
alkyl
het
Prior art date
Application number
PCT/EP1995/000872
Other languages
English (en)
Inventor
Guy Marguerite Marie Gérard NADLER
Original Assignee
Smithkline Beecham Laboratoires Pharmaceutiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Laboratoires Pharmaceutiques filed Critical Smithkline Beecham Laboratoires Pharmaceutiques
Priority to PCT/EP1995/000872 priority Critical patent/WO1996027595A1/fr
Priority to AU19497/95A priority patent/AU1949795A/en
Publication of WO1996027595A1 publication Critical patent/WO1996027595A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/70—Nitro radicals
    • C07D307/71—Nitro radicals attached in position 5
    • C07D307/72—Nitro radicals attached in position 5 with hydrocarbon radicals, substituted by nitrogen-containing radicals, attached in position 2
    • C07D307/73—Nitro radicals attached in position 5 with hydrocarbon radicals, substituted by nitrogen-containing radicals, attached in position 2 by amino or imino, or substituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/42—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms

Definitions

  • the invention relates to certain novel compounds, to pharmaceutical compositions containing such compounds, to a process for the preparation of such compounds and to the use of such compounds as active therapeutic agents, particularly in the treatment of atrial or ventricular cardiac arrhythmias.
  • Anti-arrhythmic agents are classified according to their electrophysiological effects on the cardiac cell (Vaugham- Williams, 1970, 1989) : class I agents block the fast sodium current, class II agents are beta-adrenergic blockers, class m agents block potassium currents, class IV agents block the calcium current, and class V agents are specific sinus node inhibitors.
  • a majority of ventricular and atrial arrhythmias are related to reentrant circuit.
  • the prolongation of myocardial refractoriness within or surrounding such a reentrant circuit is a potential mechanism for the management of cardiac arrhythmias.
  • class III antiarrhythmic agents block cardiac potassium currents, they prolong the repolarisation process and increase refractoriness. Consequently class III agents represent the most specific class to treat reentrant arrhythmias.
  • higher doses of class III antiarrhythmic agents may trigger arrhythmias.
  • Such arrhythmias called Torsade de Pointe generally represents the main adverse effect for all pure class III compound currently in development.
  • European Patent Application, Publication Number 0233762 discloses a class of compounds of formula A
  • Rj and R4 are independently phenyl optionally substituted by one, two or three of halogen, trifluoromethyl, C1.4 alkoxy, C ⁇ __ ⁇ alkyl, cyano, hydroxy, nitro, NR5 R or O2SNR5 Rg wherein R5 and Rg are independently hydrogen or C __ alkyl or together are C3.6 polymethylene, or disubstituted at adjacent carbon atoms by C1.2 alkylenedioxy and optionally further substituted by one of the above groups; R2 is selected from (CH2) Z CN where z is zero or an integer from 1 to 4, C ⁇ _ ⁇ 2 alkyl,
  • a and B each independently represents a C ⁇ __ n-alkylene group wherein each carbon is optionally substituted by a C j .5 alkyl group;
  • D represents CO, SO2, NH-CO or CH2CO
  • T represents hydrogen, alkyl, alkene or cycloalkyl
  • Het represents substituted or unsubstituted: furanyl, pyranyl, thienyl, thiazolyl, imidazolyl, triazolyl or the benzo fused equivalents of furanyl, pyranyl, thienyl, thiazolyl, imidazolyl or triazolyl, indolyl, oxoindolyl, indenyl, isoindenyl, indazolyl, indolizinyl, or benzofurazanyl; optional substituents for the moiety Het include 1 to 5 substituents selected from the list consisting of nitro, halogen, alkylsulfonamido, alkylamido, IH-imidazolyl, alkyl and haloalkyl;
  • Rj, R2 and R3 each independently represent H, alkyl, OH or alkoxy or, if attached to adjacent carbon atoms, any two of Rj, R2 or R3 together with the carbon atoms to which they are attached may form a fused heterocyclic ring of five to six atoms wherein one, two or three of the said atoms are oxygen or nitrogen;
  • Z represents a bond, CH2, (CH2>2 or X-CH2-CH2 wherein X represents O or S; and
  • Ar represents substituted or unsubstituted aryl, wherein the optional substituents are the above defined RjS 2 and R3
  • A represents (CH2)3-
  • B represents CH2CH2.
  • D represents CO, SO2, NH-CO or CH2CO.
  • T represents 0 * 3 .
  • Rj, R2 and R3 represents alkoxy, for example methoxy, the remaining member(s) being H.
  • Het includes furanyl and thienyl.
  • Het is sustituted by 1,2 or 3 substituents, favourably 1.
  • An example of a substitutent for Het is a nitro group.
  • Het are 4-nitro-2-thiophenyl, 5-nitro-2-furanyl and 5- benzofurazanyl.
  • alkyl includes straight or branched chain alkyl groups having from 1 to 12, favourably 1 to 6, carbon atoms and shall include such alkyl groups when forming pan of other groups such as alkoxy or arylalkyl groups.
  • alkenyl includes straight or branched chain alkylene groups having from 2 to 12, favourably 2 to 6, carbon atoms and one or more double bonds.
  • aryl includes phenyl and naphthyl, preferably phenyl.
  • cycloalkyl includes C3-8 preferably C4.6 cycloalkyl groups.
  • halogen includes fluorine, chlorine or bromine.
  • cardiac arrhythmia relates to any variation from the normal rhythm of heart beat, including, without limitation, sinus arrhythmia, premature heartbeat, heartblock, fibrillation, flutter, tachycardia, paroxysmal tachycardia and premature ventricular contractions.
  • the compounds of formula (I) may possess chiral carbon atoms and therefore may exist in more than one stereoisomeric form.
  • the invention extends to any of the stereoisometric forms, including enantiomers of the compounds of formula (I) and to mixtures thereof, including racemates. The different stereoisomeric forms may be
  • the pharmaceutically acceptable salts of the compounds of formula (I) include acid addition salts with pharmaceutically acceptable mineral acids such as hydrochloric, hydrobromic, boric, phosphoric, sulphuric and pharmaceutically acceptable organic acids such as acetic, tartaric, maleic, citric, succinic, benzoic, ascorbic, methanesulphonic, a-keto-glutaric, a-glycerophosphoric, and glucose- 1- phosphoric acids.
  • pharmaceutically acceptable mineral acids such as hydrochloric, hydrobromic, boric, phosphoric, sulphuric
  • pharmaceutically acceptable organic acids such as acetic, tartaric, maleic, citric, succinic, benzoic, ascorbic, methanesulphonic, a-keto-glutaric, a-glycerophosphoric, and glucose- 1- phosphoric acids.
  • the acid addition salt is a hydrochloride.
  • Pharmaceutically acceptable salts also include quaternary salts.
  • quaternary salts include such compounds quatemised by compounds such as R z -T ⁇ wherein R z is C ⁇ __ alkyl, phenyl-Cj.g alkyl or C5.7 cycloalkyl, and T is a radical corresponding to an anion of an acid.
  • R z include methyl, ethyl and n- and iso- propyl; and benzyl and phenethyl.
  • T* includes halide such as chloride, bromide and iodide.
  • Pharmaceutically acceptable salts also include pharmaceutically acceptable N- oxides, and the invention extends to these.
  • the compounds of the formula (I) and their salts may also form solvates, especially pharmaceutically acceptable solvates, such as hydrates, and the invention extends to these, and especially to the pharmaceutically acceptable solvates.
  • the salts of the compounds of the formula (I) which are not pharmaceutically acceptable may be useful as intermediates in the preparation of pharmceutically acceptable salts of compounds of formula (I) or the compounds of the formula (I) themselves, and as such form an aspect of the present invention.
  • a compound of formula (I) or a salt thereof, or a solvate thereof may be prepared by reacting a compound of formula (II):
  • Het-X wherein Het is as defined in relation to formula (I) and:
  • reaction conditions for the reaction between compounds of formulae (II) and (III) are conventional conditions appropriate to the nature of the reagent used, generally however the reaction may be carried out in an inert solvent, such as methylene chloride, at any suitable temperature providing a convenient rate of formation of the desired product, generally at an ambient to elevated temperature, conveniently at the reflux temperature of the solvent and preferably in the presence of a base such as triethylamine.
  • an inert solvent such as methylene chloride
  • Compounds of formula (II) are known compounds or they may be obtained by procedures analogous to those used to prepare known compounds, for example as described in EP 0 233 762.
  • Suitable protecting groups in any of the abovementioned reactions are those used conventionally in the art.
  • the methods of formation and removal of such protecting groups are those conventional methods appropriate to the molecule being protected.
  • the present invention accordingly provides a compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use as an active therapeutic substance. More particularly, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use in the treatment of and/or prophylaxis of arrhythmia, especially cardiac arrhythmia such as ventricular arrhythmia, and also ischeamic rhythm disorders. A compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, may be administered per. SS.
  • the present invention also provides a pharmaceutical composition comprising a compound of the general formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier thereof.
  • a compound of formula (I) or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof is normally administered in unit dosage form.
  • An amount effective to treat the disorder hereinbefore described depends upon such factors as the efficacy of a compound of formula (I) , the particular nature of the pharmaceutically acceptable salt or pharmaceutically acceptable solvate chosen, the nature and severity of the disorders being treated and the weight of the mammal.
  • a unit dose will normally contain 1 to 50 mg for example 2 to 15 mg, of the compound of the invention.
  • Unit doses will normally be administered once or more than once a day, for example 2, 3, 4, 5 or 6 times a day, more usually 2 to 4 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 1 to 300 mg, more usually 4 to 100 mg, for example 10 to 60mg, that is in the range of approximately 0.02 to 5 mg kg/day, more usually 0.1 to 2 mg/kg day, for example 0.1 to 0.5 mg/kg/day.
  • the compound may be administered by any suitable route, e.g. by the oral, parenteral or topical routes.
  • the compound will normally be employed in the form of a pharmaceutical composition in association with a human or veterinary pharmaceutical carrier, diluent and/or excipient, although the exact form of the composition will naturally depend on the mode of administration.
  • compositions are prepared by admixture and are suitably adapted for oral, parenteral or topical administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, pastilles, reconstitutable powders, injectable and infusable solutions or suspensions, suppositories and transdermal devices.
  • Orally administrate compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use.
  • Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents.
  • the tablets may be coated according to well known methods in the art.
  • Suitable fillers for use include cellulose, mannitol, lactose and other similar agents.
  • Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate.
  • Suitable lubricants include, for example, magnesium stearate.
  • Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
  • Solid oral compositions may be prepared by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for e ⁇ .ample sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p.-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • suspending agents for e ⁇ .ample sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lec
  • fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle.
  • the compound depending on the vehicle and the concentration, can be either suspended or dissolved.
  • Parenteral solutions are normally prepared by dissolving the active compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner except that the active compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the active compound.
  • the composition may be in the form of a transdermal ointment or patch for systemic delivery of the compound .and may be prepared in a conventional manner, for example, as described in the standard textbooks such as 'Dermatological Formulations' - B.W. Barry (Drugs and the Pharmaceutical Sciences - Dekker) or Harrys Cosmeticology (Leonard Hill Books).
  • compositions may contain further active agents such as anti-hypertensive agents and diuretics.
  • compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.
  • pharmaceutically acceptable embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable .salt' embraces a veterinarily acceptable salt
  • the present invention further provides a method for the treatment and/or prophylaxis of arrhythmia, especially cardiac arrhydimia such as ventricular arrhythmia, and also ischemic rhythm disorders in a human or non-human mammal which comprises administering an effective, non-toxic, amount of a compound of the general formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof to a human or non-human mammal in need thereof.
  • the active ingredient may be administered as a pharmaceutical composition hereinbefore defined, and this forms a particular aspect of the present invention.
  • the compound of the general formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof may be taken in doses, such as those described above.
  • the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for the manufacture of a medicament for the treatment of arrhythmia, especially cardiac arrhythmia such as ventricular arrhythmia, and also ischemic rhythm disorders.
  • Guinea pigs (300-350 g) were anesthetized by intravenous injection of sodium pentobarbital (60 mg/kg). After thoracotomy the hea ⁇ was rapidly excised and placed in oxygenated Tyrode solution. Papillary muscles were removed from the right ventricle. Preparations were then fixed to the silastic base of a 5 ml organ bath and superfused with oxygenated Tyrode solution maintained at 37 ⁇ 1°C.
  • the modified Tyrode solution (pH 7.35) contained the following (mM) : NaCl 125, KCl 4.0, MgCl 2 0.5, CaCl 2 1.8, NaHCO324, NaH 2 PO 0.9 and glucose 5.5.
  • the solution was equilibrated with a gas mixture of 95% O2 - 5% CO2. After a stabilisation period (at least lh), transmembrane action potentials were recorded with conventional microelectrodes (10 MOhm) connected to a high input impedance amplifier (BIOLOGIC VF 180). External stimuli were delivered to the preparation with bipolar platinum electrodes placed at one end of the muscle. The pulse duration was 1 ms and the amplitude was twice threshold. The basic cycle length was 1000 ms (PULSAR 6i stimulator). The signals were monitored on a storage oscilloscope (GOULD 1602) and simultaneously recorded on a digital tape recorder (BIOLOGIC DTR 1200) for further analysis.
  • RMP resting membrane potential
  • APA action potential amplitude
  • APD30, APD50 and APD90 90% repolarization
  • Action potential duration was measured at 30% (APD30), 50%(APD50) and 90% (APD90) of repolarization.
  • Action potential duration was measured at 30% (APD30), 50%(APD50) and 90% (APD90) of repolarization.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé de la formule (I) ou un sel ou solvate de ce composé. Dans cette formule, A et B représentent chacun indépendamment un groupe n-alkylène C1-4 dans lequel chaque atome de carbone est éventuellement substitué par un groupe alkyle C1-6; D représente CO, SO2, NH-CO ou CH2CO; T représente hydrogène, alkyle, alcène ou cycloalkyle; et Het représente furanyle, pyranyle, thiényle, thiazolyle, imidazolyle, triazolyle ou les équivalents benzo-fusionnés de furanyle, pyranyle, thiényle, thiazolyle, imidazolyle ou triazolyle, indolyle, oxoindolyle, indényle, isoindényle, indazolyle, indolizinyle, ou benzofurazanyle, tous éventuellement substitués; les substituants éventuels pour la fraction Het comprennent 1 à 5 substituants choisis parmi nitro, halogène, alkylsulfonamido, alkylamido, 1H-imidazolyle, alkyle et haloalkyle; R1, R2 et R3 représentent chacun indépendamment H, alkyle, OH ou alcoxy, ou, s'ils sont rattachés à des atomes de carbone adjacents, n'importe quels deux symboles choisis entre R1, R2 et R3 peuvent former, avec les atomes de carbone auxquels ils sont rattachés, un noyau hétérocyclique fusionné renfermant cinq à six atomes, dont un, deux ou trois sont des atomes d'oxygène ou d'azote; Z représente une liaison, CH2, (CH2)2 ou X-CH2-CH2, X représentant O ou S; et Ar représente aryle substitué ou non, dans lequel les éventuels substituants sont R1, R2 et R3, tels que définis ci-dessus. Une composition contenant un tel composé, un procédé de préparation de ce composé et son utilisation pour le traitement et/ou la prophylaxie de l'arythmie cardiaque sont également décrits.
PCT/EP1995/000872 1995-03-08 1995-03-08 Heterocyclylcarboxamides et autres composes utilises pour le traitement des arythmies cardiaques WO1996027595A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/EP1995/000872 WO1996027595A1 (fr) 1995-03-08 1995-03-08 Heterocyclylcarboxamides et autres composes utilises pour le traitement des arythmies cardiaques
AU19497/95A AU1949795A (en) 1995-03-08 1995-03-08 Heterocyclycarboxamides and other compounds for the treatment of the cardiac arrhythmias

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1995/000872 WO1996027595A1 (fr) 1995-03-08 1995-03-08 Heterocyclylcarboxamides et autres composes utilises pour le traitement des arythmies cardiaques

Publications (1)

Publication Number Publication Date
WO1996027595A1 true WO1996027595A1 (fr) 1996-09-12

Family

ID=8165969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/000872 WO1996027595A1 (fr) 1995-03-08 1995-03-08 Heterocyclylcarboxamides et autres composes utilises pour le traitement des arythmies cardiaques

Country Status (2)

Country Link
AU (1) AU1949795A (fr)
WO (1) WO1996027595A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103012381A (zh) * 2013-01-10 2013-04-03 山东大学 苯基呋喃类化合物、其制备方法及在制备抗心律失常药物中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233762A2 (fr) * 1986-02-15 1987-08-26 BEECHAM - WUELFING GmbH & Co. KG Utilisation de diamines aromatiques pour le traitement de l'angine de poitrine et diamines à cet usage
EP0300865A1 (fr) * 1987-07-16 1989-01-25 Synthelabo Dérivés de N-aminobutyl N-phényl arylamides, leur préparation et leur application en thérapeutique
FR2636631A1 (fr) * 1988-09-21 1990-03-23 Kotobuki Seiyaku Co Ltd Derives diamines du thiophene, procede pour les preparer et compositions anti-arythmiques les contenant
EP0431944A2 (fr) * 1989-12-08 1991-06-12 Merck & Co. Inc. Dérivés de benzofurazane possédant des propriétés antiarythmiques
FR2691064A1 (fr) * 1992-05-14 1993-11-19 Beecham Laboratoires Nouveau médicament pour le traitement de l'arythmie.
WO1995007903A1 (fr) * 1993-09-13 1995-03-23 Smithkline Beecham Laboratoires Pharmaceutiques Derives heterocycliques de carboxamide ayant une activite antiarythmique

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233762A2 (fr) * 1986-02-15 1987-08-26 BEECHAM - WUELFING GmbH & Co. KG Utilisation de diamines aromatiques pour le traitement de l'angine de poitrine et diamines à cet usage
EP0300865A1 (fr) * 1987-07-16 1989-01-25 Synthelabo Dérivés de N-aminobutyl N-phényl arylamides, leur préparation et leur application en thérapeutique
FR2636631A1 (fr) * 1988-09-21 1990-03-23 Kotobuki Seiyaku Co Ltd Derives diamines du thiophene, procede pour les preparer et compositions anti-arythmiques les contenant
EP0431944A2 (fr) * 1989-12-08 1991-06-12 Merck & Co. Inc. Dérivés de benzofurazane possédant des propriétés antiarythmiques
FR2691064A1 (fr) * 1992-05-14 1993-11-19 Beecham Laboratoires Nouveau médicament pour le traitement de l'arythmie.
WO1995007903A1 (fr) * 1993-09-13 1995-03-23 Smithkline Beecham Laboratoires Pharmaceutiques Derives heterocycliques de carboxamide ayant une activite antiarythmique

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103012381A (zh) * 2013-01-10 2013-04-03 山东大学 苯基呋喃类化合物、其制备方法及在制备抗心律失常药物中的应用
CN103012381B (zh) * 2013-01-10 2015-01-07 山东大学 苯基呋喃类化合物、其制备方法及在制备抗心律失常药物中的应用

Also Published As

Publication number Publication date
AU1949795A (en) 1996-09-23

Similar Documents

Publication Publication Date Title
EP0700385A1 (fr) Nouveaux composes
US4797406A (en) Amides and esters containing bridged piperidines and use as serotonin M antagonists
DE69211951T2 (de) Kondensierte Benzenoxyessigsäurederivate als PGI2-Rezeptoragonisten
EP0416581A1 (fr) N-Benzylpipéridine amides substitués
EP0700389A1 (fr) 3-benzazepines ou isoquinolines n-substituees a action antiarythmique
US5977179A (en) Nitro-benzamides useful as anti-arrhythmic agents
EP0719263B1 (fr) Derives heterocycliques de carboxamide ayant une activite antiarythmique
WO1996027595A1 (fr) Heterocyclylcarboxamides et autres composes utilises pour le traitement des arythmies cardiaques
US5712284A (en) Azalicyclooctane derivatives as anti-arrhythmic agents
WO1995007884A1 (fr) Derives alcanediamine et leur utilisation dans le traitement de l'arythmie et des troubles du rythme ischemique
MXPA97003112A (en) Nitro-benzamides useful as agentesantiarritmi
CA2386845A1 (fr) Hydrochlorure de benzamide n-¬3-¬¬2-(3,4-dimethexyphenyl)ethyl|amino|propyl|-4-nitro polymorphe
FR2705674A1 (fr) Nouveaux composés et leur procédé de préparation et leur utilisation en tant que médicaments.
JPS62153268A (ja) 置換フエノキシプロピルアミド誘導体の製造法
FR2705675A1 (fr) Nouveaux composés, leur procédé de préparation et leur utilisation en tant que médicaments.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU KE KG KP KR KZ LK LR LT LV MD MG MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: MX

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载